Rollover Protocol for Prior SU011248 Protocols

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT00798889
First received: November 25, 2008
Last updated: December 13, 2012
Last verified: December 2012
  Purpose

The objective of this protocol is to provide SU011248 treatment for patients who have participated in a SU011248 protocol and are eligible to enter this protocol


Condition Intervention
Solid Tumors
Drug: Sunitinib

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol

Resource links provided by NLM:


Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Duration of Treatment [ Time Frame: Baseline up to Day 28 after last dose of study treatment ] [ Designated as safety issue: Yes ]

Enrollment: 314
Study Start Date: March 2004
Study Completion Date: December 2011
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Sunitinib Drug: Sunitinib
Sunitinib dose varies according to the doses allowed in previous protocol. It is given once a day, orally with various schedules depending on the parent protocol

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Prior SU011248 Protocol.
  • Eligible to continue SU011248 treatment.

Exclusion Criteria:

  • Uncontrolled CNS metastasis.
  • Unfit to receive SU011248.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00798889

  Hide Study Locations
Locations
United States, Alabama
Pfizer Investigational Site
Birmingham, Alabama, United States, 35233
Pfizer Investigational Site
Birmingham, Alabama, United States, 35294
Pfizer Investigational Site
Birmingham, Alabama, United States, 35233-2115
United States, California
Pfizer Investigational Site
Los Angeles, California, United States, 90033
Pfizer Investigational Site
Los Angeles, California, United States, 90095
Pfizer Investigational Site
San Francisco, California, United States, 94115-1705
Pfizer Investigational Site
San Francisco, California, United States, 94115
Pfizer Investigational Site
Santa Monica,, California, United States, 90404
United States, Colorado
Pfizer Investigational Site
Aurora, Colorado, United States, 80045
United States, Indiana
Pfizer Investigational Site
Indianapolis, Indiana, United States, 46202
United States, Massachusetts
Pfizer Investigational Site
Boston, Massachusetts, United States, 02115
Pfizer Investigational Site
Boston, Massachusetts, United States, 02114
Pfizer Investigational Site
Boston, Massachusetts, United States, 02215
United States, Michigan
Pfizer Investigational Site
Ann Arbor, Michigan, United States, 48109-0843
Pfizer Investigational Site
Detroit, Michigan, United States, 48201
Pfizer Investigational Site
Farmington Hills, Michigan, United States, 48334
United States, Minnesota
Pfizer Investigational Site
Minneapolis, Minnesota, United States, 55455-0392
United States, Missouri
Pfizer Investigational Site
St. Louis, Missouri, United States, 63110
United States, New Mexico
Pfizer Investigational Site
Albuquerque, New Mexico, United States, 87131-0001
Pfizer Investigational Site
Albuqurque, New Mexico, United States, 87106
United States, New York
Pfizer Investigational Site
New York, New York, United States, 10021
Pfizer Investigational Site
New York, New York, United States, 10022
Pfizer Investigational Site
New York, New York, United States, 10032
United States, North Carolina
Pfizer Investigational Site
Durham, North Carolina, United States, 27710
United States, Ohio
Pfizer Investigational Site
Cleveland, Ohio, United States, 44195
United States, Pennsylvania
Pfizer Investigational Site
Philadelphia, Pennsylvania, United States, 19111
United States, South Carolina
Pfizer Investigational Site
Myrtle Beach, South Carolina, United States, 29572
United States, Tennessee
Pfizer Investigational Site
Franklin, Tennessee, United States, 37067
Pfizer Investigational Site
Gallatin, Tennessee, United States, 37066
Pfizer Investigational Site
Hermitage, Tennessee, United States, 37076
Pfizer Investigational Site
Lebanon, Tennessee, United States, 37087
Pfizer Investigational Site
Murfreesboro, Tennessee, United States, 37130
Pfizer Investigational Site
Nashville, Tennessee, United States, 37207
Pfizer Investigational Site
Nashville, Tennessee, United States, 37232
Pfizer Investigational Site
Nashville, Tennessee, United States, 37212
Pfizer Investigational Site
Nashville, Tennessee, United States, 37203
Pfizer Investigational Site
Nashville, Tennessee, United States, 37211
Pfizer Investigational Site
Nashville, Tennessee, United States, 37205
Pfizer Investigational Site
Smyrna, Tennessee, United States, 37167
United States, Texas
Pfizer Investigational Site
Dallas, Texas, United States, 75246
Pfizer Investigational Site
Houston, Texas, United States, 77030-4009
United States, Wisconsin
Pfizer Investigational Site
Madison, Wisconsin, United States, 53792
Australia, New South Wales
Pfizer Investigational Site
Randwick, New South Wales, Australia, 2031
Australia, Victoria
Pfizer Investigational Site
East Melbourne, Victoria, Australia, 3002
Pfizer Investigational Site
Heidelberg, Victoria, Australia, 3084
Canada, Quebec
Pfizer Investigational Site
Montreal, Quebec, Canada, H2L 4M1
France
Pfizer Investigational Site
Villejuif Cedex, France, 94805
Greece
Pfizer Investigational Site
Thessaloniki, Greece, 564 03
Italy
Pfizer Investigational Site
Milano, Italy, 20133
Pfizer Investigational Site
Milano, Italy, 20141
Netherlands
Pfizer Investigational Site
Nijmegen, Gld, Netherlands, 6525 GA
Singapore
Pfizer Investigational Site
Singapore, Singapore, 308433
Sweden
Pfizer Investigational Site
Lund, Sweden
Pfizer Investigational Site
Stockholm, Sweden
Switzerland
Pfizer Investigational Site
St. Gallen, Switzerland, CH-9007
United Kingdom
Pfizer Investigational Site
Leeds, United Kingdom, LS9 7TF
Pfizer Investigational Site
London, United Kingdom, NW1 2PG
Pfizer Investigational Site
London, United Kingdom, SW3 6JJ
Pfizer Investigational Site
Newcastle-Upon-Tyne, United Kingdom, NE4 6BE
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
No publications provided

Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT00798889     History of Changes
Other Study ID Numbers: A6181030
Study First Received: November 25, 2008
Results First Received: December 13, 2012
Last Updated: December 13, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Pfizer:
Solid tumors

Additional relevant MeSH terms:
Sunitinib
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors

ClinicalTrials.gov processed this record on September 30, 2014